IMUGENE LIMITED — Board/Management Information 2018

Sep 17, 2018

ASX Announcement

==> picture [168 x 75] intentionally omitted <==

Imugene appoints gastrointestinal cancer expert to Scientific Advisory Board

Sydney, Australia - 18 September 2018 – Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company today announced the appointment of Professor Tanios Bekaii-Saab of the Mayo Clinic College of Medicine and Science to its Scientific Advisory Board (SAB).

Imugene Managing Director and CEO Leslie Chong said, “Professor Bekaii-Saab is a recognised leader in gastrointestinal treatment and research. We look forward to the insights he will provide as the team at Imugene progresses its cancer immuno-therapy product pipeline.”

Prof Bekaii-Saab is the principal investigator on numerous clinical trials focused on new targeted and immune therapies in gastrointestinal malignancies. He is co-leader of the Gastrointestinal Cancer Program at the Mayo Clinic Cancer Center, medical director of the Cancer Clinical Research Office and a senior associate consultant in the Division of Hematology/Oncology in the Department of Internal Medicine at the Mayo Clinic in Phoenix, Arizona.

The Mayo Clinic is widely acknowledged as one of the world's leading nonprofit academic medical care, education and research institutions at the forefront of medical innovation.

Prof Bekaii-Saab is a member of the American Society of Clinical Oncology, American Association for Cancer Research and the American College of Physicians. In addition he is co-leader of the Hepatobiliary Cancer Committee of the Alliance for Clinical Trials in Oncology Cooperative Group and the representative for the National Cancer Institute’s Hepatobiliary Task Force, as well as the Southwest Oncology Group representative for the National Cancer Institute’s Pancreatic Cancer Task Force.

IMUGENE LIMITED ACN 009 179 551 Phone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com

He has authored or co-authored more than 350 peer reviewed publications, abstracts, and book chapters in journals such as Lancet Oncology , Journal of Clinical Oncology, JAMA, Journal of the National Cancer Institute, Annals of Oncology, and Clinical Cancer Research .

For more information please contact:

Leslie Chong

Managing Director and Chief Executive Officer

T: +61 458 040 433

Follow us on Twitter @ TeamImugene

About Imugene (ASX:IMU)

Imugene is a clinical stage immuno-oncology company developing a range of new and novel immunotherapies that seek to activate the immune system of cancer patients to treat and eradicate tumors. Our unique platform technology seeks to harness the body’s immune system to generate antibodies against tumours, potentially achieving a similar or greater effect than synthetically manufactured monoclonal antibody therapies. Our product pipeline includes multiple immunotherapy B-cell vaccine candidates aimed at treating a variety of cancers in combination with standard of care drugs and emerging immunotherapies. We are supported by a leading team of international cancer experts with extensive experience in developing new cancer therapies with many approved for sale and marketing for global markets. Our vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments. This vision is backed by a growing body of clinical evidence and peerreviewed research. Imugene is well funded and resourced, to deliver on its commercial and clinical milestones. Together with leading specialists and medical professionals, we believe Imugene’s immuno-oncology therapies will become a foundation treatment for cancer. Our goal is to ensure Imugene and its shareholders are at the forefront of this rapidly growing global market.

IMUGENE LIMITED ACN 009 179 551 Phone +61 3 9824 5254 Fax +61 3 9822 7735 Website www.imugene.com

2